321 related articles for article (PubMed ID: 24475542)
1. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
Ausness RC
Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
[TBL] [Abstract][Full Text] [Related]
2. Preemption of the "fraud on the FDA" exception to Michigan's tort immunity statute for drug manufacturers: reconsidering Garcia and Desiano after Levine.
Murdey J
Food Drug Law J; 2011; 66(1):85-104, ii-iii. PubMed ID: 24505848
[TBL] [Abstract][Full Text] [Related]
3. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
Kesselheim AS
Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
[TBL] [Abstract][Full Text] [Related]
4. How the FDA can overturn Wyeth v. Levine.
Gostanian A
Am J Law Med; 2010; 36(1):248-68. PubMed ID: 20481407
[TBL] [Abstract][Full Text] [Related]
5. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
Smirniotopoulos A
Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
[TBL] [Abstract][Full Text] [Related]
6. Tort reform by regulation: FDA prescription drug labeling rules and preemption of state tort claims.
Moreland MP
J Health Life Sci Law; 2007; 1(1):39, 41-62. PubMed ID: 18610730
[TBL] [Abstract][Full Text] [Related]
7. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
8. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
Gaddis CA
Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
[TBL] [Abstract][Full Text] [Related]
9. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
Rostron A
Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
[TBL] [Abstract][Full Text] [Related]
10. The demise of drug design litigation: death by federal preemption.
Twerski AD
Am Univ Law Rev; 2018; 68(1):281-304. PubMed ID: 30457769
[TBL] [Abstract][Full Text] [Related]
11. A strike against preemption.
Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
[TBL] [Abstract][Full Text] [Related]
12. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
Wartman GJ
Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
[TBL] [Abstract][Full Text] [Related]
13. FDA preemption of drug and device labeling: who should decide what goes on a drug label?
Valoir T; Ghosh S
Health Matrix Clevel; 2011; 21(2):555-98. PubMed ID: 22145525
[TBL] [Abstract][Full Text] [Related]
14. Guide to preemption of state-law claims against Class III PMA medical devices.
Whitney DW
Food Drug Law J; 2010; 65(1):113-39, ii-iii. PubMed ID: 24475536
[TBL] [Abstract][Full Text] [Related]
15. The Supreme Court, preemption, and malpractice liability.
Kesselheim AS; Studdert DM
N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
[No Abstract] [Full Text] [Related]
16. Wyeth v Levine: implications for public health policy and practice.
David S; Rosenbaum S
Public Health Rep; 2010; 125(3):494-7. PubMed ID: 20433045
[No Abstract] [Full Text] [Related]
17. FDA's regulation of prescription drug labeling: a role for implied preemption.
Kendrick LC
Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
[No Abstract] [Full Text] [Related]
18. Wyeth preemption case ruling sparks labeling confusion.
Allison M
Nat Biotechnol; 2009 May; 27(5):399-400. PubMed ID: 19430423
[No Abstract] [Full Text] [Related]
19. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
Boumil MM; Curfman G
JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
[No Abstract] [Full Text] [Related]
20. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation.
Morten CJ; Kesselheim AS; Ross JS
J Law Med Ethics; 2019 Dec; 47(4):783-787. PubMed ID: 31957583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
